CT1113 / Chaser Therapeutics - LARVOL DELTA

CT1113, a dual USP25/28 inhibitor, promotes antitumor immunity by preventing YTHDF2-mediated complement activation and potentiates anti-PD-1 therapy (AACR 2025) - "As a result, both pharmacologic and genetic inhibition of USP25/28 strongly enhance anti-PD-1 therapy against two murine "cold" tumor models without discernable systemic toxicity. Together, these results provide a rationale for future clinical trials evaluating the synergy between inhibiting USP25/28 and ICI to improve the efficacy of immunotherapy."

Late-breaking abstract • Oncology • CD8 • USP25 • YTHDF2

The first-in-human trial of USP28 inhibitor CT1113 (AACR 2025) - "Importantly, preliminary efficacy was observed, validating USP28 as a therapeutic target. A phase II trial has been planned."

P1 data • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology • MYC